Literature DB >> 21717439

Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome.

Iris Cordoba1, José R González-Porras, Benet Nomdedeu, Elisa Luño, Raquel de Paz, Esperanza Such, Mar Tormo, Teresa Vallespi, Rosa Collado, Blanca Xicoy, Rafael Andreu, Juan A Muñoz, Francesc Solé, Jose Cervera, Consuelo del Cañizo.   

Abstract

BACKGROUND: Abnormalities involving chromosome 7 are frequent in myelodysplastic syndrome (MDS) and suggest a poor prognosis.
METHODS: The authors examined the hypothesis that the clinical features and survival associated with isolated deletion (del) of part of the long arm of chromosome 7 (7q) in MDS are different from those associated with isolated monosomy 7 (complete loss of chromosome 7). In total, 133 patients with a diagnosis of de novo MDS (according to the World Health Organization [WHO] classification) and chromosome 7 abnormalities in the Spanish MDS Registry were evaluated retrospectively. Four karyotypic groups were identified: isolated del(7q) (n = 29), isolated monosomy 7 (n = 27), del(7q) with additional abnormalities (n = 24), and monosomy 7 with additional abnormalities (n = 53).
RESULTS: Isolated del(7q) was more frequent in patients with less advanced MDS according to the WHO classification or the International Prognostic Scoring System. In addition, isolated del(7q) was associated with fewer blasts in bone marrow than other cytogenetics groups. Survival was significantly superior in patients with isolated del(7) than in those with isolated monosomy 7, del(7q) with additional abnormalities, or monosomy 7 with additional abnormalities. On multivariate analysis, age, the percentage of blasts in bone marrow, and other chromosome 7 abnormalities apart from isolated del(7q) were identified as independent risk factors for survival.
CONCLUSIONS: The current results demonstrated that patients who had MDS with isolated del(7q) had some distinct clinical-pathologic characteristics as well as better survival than patients who had MDS with isolated monosomy 7.
Copyright © 2011 American Cancer Society.

Entities:  

Mesh:

Year:  2011        PMID: 21717439     DOI: 10.1002/cncr.26279

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

1.  Newly emerged isolated Del(7q) in patients with prior cytotoxic therapies may not always be associated with therapy-related myeloid neoplasms.

Authors:  Rashmi S Goswami; Sa A Wang; Courtney DiNardo; Zhenya Tang; Yan Li; Wenli Zuo; Shimin Hu; Shaoying Li; L Jeffrey Medeiros; Guilin Tang
Journal:  Mod Pathol       Date:  2016-04-08       Impact factor: 7.842

2.  Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis.

Authors:  Andres Jerez; Yuka Sugimoto; Hideki Makishima; Amit Verma; Anna M Jankowska; Bartlomiej Przychodzen; Valeria Visconte; Ramon V Tiu; Christine L O'Keefe; Azim M Mohamedali; Austin G Kulasekararaj; Andrea Pellagatti; Kathy McGraw; Hideki Muramatsu; Alison R Moliterno; Mikkael A Sekeres; Michael A McDevitt; Seiji Kojima; Alan List; Jacqueline Boultwood; Ghulam J Mufti; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2012-05-02       Impact factor: 22.113

Review 3.  The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia.

Authors:  Adam S Sperling; Christopher J Gibson; Benjamin L Ebert
Journal:  Nat Rev Cancer       Date:  2016-11-11       Impact factor: 60.716

Review 4.  Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia.

Authors:  T Bochtler; S Fröhling; A Krämer
Journal:  Leukemia       Date:  2015-02-12       Impact factor: 11.528

Review 5.  The significance of CUX1 and chromosome 7 in myeloid malignancies.

Authors:  Matthew R M Jotte; Megan E McNerney
Journal:  Curr Opin Hematol       Date:  2022-03-01       Impact factor: 3.284

6.  Predictors of clonal evolution and myeloid neoplasia following immunosuppressive therapy in severe aplastic anemia.

Authors:  Emma M Groarke; Bhavisha A Patel; Ruba Shalhoub; Fernanda Gutierrez-Rodrigues; Parth Desai; Harshraj Leuva; Yoshitaka Zaimoku; Casey Paton; Nina Spitofsky; Jennifer Lotter; Olga Rios; Richard W Childs; David J Young; Alina Dulau-Florea; Cynthia E Dunbar; Katherine R Calvo; Colin O Wu; Neal S Young
Journal:  Leukemia       Date:  2022-07-27       Impact factor: 12.883

7.  Specific genomic regions are differentially affected by copy number alterations across distinct cancer types, in aggregated cytogenetic data.

Authors:  Nitin Kumar; Haoyang Cai; Christian von Mering; Michael Baudis
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

8.  A ceRNA approach may unveil unexpected contributors to deletion syndromes, the model of 5q- syndrome.

Authors:  Walter Arancio; Swonild Ilenia Genovese; Lucia Bongiovanni; Claudio Tripodo
Journal:  Oncoscience       Date:  2015-11-11

9.  Secondary myeloid neoplasias: an emerging group of diseases.

Authors:  Jesús M Hernández-Rivas
Journal:  Rev Bras Hematol Hemoter       Date:  2011

10.  Application of array comparative genomic hybridization in 256 patients with developmental delay or intellectual disability.

Authors:  Magdalena Bartnik; Beata Nowakowska; Katarzyna Derwińska; Barbara Wiśniowiecka-Kowalnik; Marta Kędzior; Joanna Bernaciak; Kamila Ziemkiewicz; Tomasz Gambin; Maciej Sykulski; Natalia Bezniakow; Lech Korniszewski; Anna Kutkowska-Kaźmierczak; Jakub Klapecki; Krzysztof Szczałuba; Chad A Shaw; Tadeusz Mazurczak; Anna Gambin; Ewa Obersztyn; Ewa Bocian; Paweł Stankiewicz
Journal:  J Appl Genet       Date:  2013-12-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.